Endoscopic Mucosal Phenotypes in the Helicobacter Pylori Infection

Open access


Introduction. H. pylori infection occurs secondary to the bacterial colonisation of the stomach and the first portion of the small intestine. Patients infected with H. pylori can develop gastritis, peptic ulcer, gastric cancer, and MALT lymphoma. H. pylori infection is defined as a type I carcinogen by the WHO, and its role in gastric carcinogenesis is sustained by many studies.

Objectives. The objective of this study was the description and correlation of the endoscopic aspect of the gastric mucosa in the Helicobacter pylori infection and the incidence in a selected patient group.

Material and method. The study was conducted in the “Dr Carol Davila” Central Military University Emergency Hospital, Section of Gastroenterology, Department of digestive endoscopy, during a period of 12 months (2012--2013) on 1690 consecutive examinations on patients with ages between 18 and 92 years, with a retrospective cohort analytic study. As diagnosis method of the individuals infected with H. pylori, upper digestive endoscopy was used.During the intervention, biopsieswere taken and rapid urease tests were performed.

Results. Regarding the variation of these endoscopic aspects within the examined population, we determined the fact that we encounter in the highest percentage gastritis with all its forms according to the Sidney classification (described below) which represents 59.3%, followed by endoscopic determination with a normal aspect in 18.8% of cases, then follows ulcer with a percentage of 10.33%, followed by duodenitis with 8.67%, and finally the most severe conditions, gastric cancer and lymphoma, reaching only 2.70% and 0.18%, respectively, of the general population examined endoscopically.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Popa Gabriela Loredana MI Popa 2008 Microbiologie Medicala Editura Tipografie

  • 2. Bȋlbȋe V Pozsgi N 1985 Bacteriologie Medicala vol II EdituraMedicala

  • 3. Boriello P Murray P Funke G editors 2005 Topley and Wilson's Microbiology and Microbial Infections 10th edition vol 1 and 2 Bacteriology Arnold ASM Press

  • 4. Buiuc D 2003 Microbiologie Medicala; Ghid pentru studiul si practica medicinei editia a VI-a Editura “Gr.T.Popa”Iasi

  • 5. Buiuc D Negut M 1999 Tratat de microbiologie clinica EdituraMedicala

  • 6. Collier Leslie Albert Balows Max Sussman editors 1998 Topley and Wilson's Microbiology and Microbacterial Infections 9th edition vol. 3 Arnold

  • 7. Dimache G Panaitescu D 2004 Bacteriologie virusologie si parazitologie medicala Editura Carol Davila

  • 8. Mandell GL Bennett JE Dolin R 2005 Mandell Douglas and Bennett's Principles and Practice of Infectious Diseases 6th ed. vol. 2 Churchill Livingstone

  • 9. Murray PR Baron EJ Pfaller MA Tenover FC Yolken RH 1995 Manual of Clinical Microbiology 6th edition ASM Press

  • 10. Murray PR Rosenthal K Kobayashi G Pfaller MA 2002Medical Microbiology 4th ed. Mosby Company

  • 11. Fiorini G Vakil N Zullo A Saracino IM Castelli V Ricci C et al. Culture-Based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection. Clin Gastroenterol Hepatol. Dec 23 2012; [Medline].

  • 12. Horiki N Omata F Uemura M et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. Oct 2009;14(5):86-90. [Medline].

  • 13. Fallone CA. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol. Nov 2000;14(10):879-82. [Medline].

  • 14. Tomb JF White O Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. Aug 7 1997;388(6642):539-47. [Medline].

  • 15. Lowenthal AC Hill M Sycuro LK et al. Functional analysis of the Helicobacter pylori flagellar switch proteins. J Bacteriol. Dec 2009;191(23):7147-56. [Medline]. [Full Text].

  • 16. Giannakis M Chen SL Karam SM et al. Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells. Proc Natl Acad Sci U S A. Mar 2008;105(11):4358-63. [Medline].

  • 17. Luther J Dave M Higgins PD Kao JY. Association between Helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature. Inflamm Bowel Dis. Sep 16 2009;epub ahead of print. [Medline].

  • 18. Jackson L Britton J Lewis SA et al. A populationbased epidemiologic study of Helicobacter pylori infection and i t s association with systemic inflammation. Helicobacter. Oct 2009;14(5):108-13. [Medline].

  • 19. Greenberg ER Anderson GL Morgan DR et al. 14- day triple 5-day concomitant and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. Aug 6 2011;378(9790):507-14. [Medline].

  • 20. [Best Evidence] Liou JM Lin JT Chang CY et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. May 2010;59(5):572-8. [Medline].

  • 21. Yoon H Kim N Lee BH et al. Moxifloxacin-containing triplse therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.Helicobacter. Oct 2009;14(5):77-85. [Medline].

  • 22. Lee SB Yang JW Kim CS. The association between conjunctival MALT lymphoma and Helicobacter pylori. Br J Internal Medicine 2019 vol. XVI No. 1 - www.srmi.ro Ophthalmol. Apr 2008;92(4):534-6. [Medline].

  • 23. Aanpreung P. Suggestive parameters for eradication therapy in children with Helicobacter pylori gastritis. JMed Assoc Thai. Nov 2005;88 Suppl 8:S21-6. [Medline].

  • 24. Adachi K Hashimoto T Komazawa Y et al. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD- -crossover comparative study with famotidine and lowdose lansoprazole. Dig Liver Dis. Jul 2005;37(7):485-90. [Medline].

  • 25. Alexander GA Brawley OW. Association of Helicobacter pylori infection with gastric cancer. Mil Med. Jan 2000;165(1):21-7. [Medline].

  • 26. Ceponis PJ Jones NL. Modulation of host cell signal transduction pathways by Helicobacter pylori infection. Can J Gastroenterol. Jul 2005;19(7):415-20. [Medline].

  • 27. Chelimsky G Czinn SJ. Helicobacter pylori infection in children: update. Curr Opin Pediatr. Oct 2000;12(5):460-2. [Medline].

  • 28. Cheng TY Lin JT Chen LT et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. Jul 20 2006;24(21):3483-9.[Medline].

  • 29. Craanen ME Blok P Dekker W et al. Helicobacter pylori and early gastric cancer. Gut. Oc t 1994;35(10):1372-4. [Medline].

  • 30. Demirel A Oncel S Caydere M et al. Helicobacter pylori infection in gastrectomy specimens. The Internet Journal of Gastroenterology 2000; 1 (1). [Full Text].

  • 31. Dunn BE Cohen H Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. Oct 1997;10(4):720-41. [Medline].

  • 32. Eaton KA Benson LH Haeger J et al. Role of transcription factor T-bet expression by CD4+ cells in gastritis due to Helicobacter pylori in mice. Infect Immun. Aug 2006;74(8):4673-84. [Medline].

  • 33. El-Omar EM Carrington M Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. Mar 23 2000;404 (6776):398-402. [Medline].

  • 34. Fischbach W. Primary gastric lymphoma of MALT: considerations of pathogenesis diagnosis and therapy.Can J Gastroenterol. Nov 2000;14 Suppl D:44D-50D. [Medline].

  • 35. Fock KM Katelaris P Sugano K et al. Second Asia- Pacific Consensus Guidelines for Helicobacter pylori infection.F J Gastroenterol Hepatol. Oct 2009;24(10) :1587-600. [Medline].

  • 36. Freston JW. Management of peptic ulcers: emerging issues. World J Surg. Mar 2000;24(3):250-5.[Medline].

  • 37. Garcia-Altes A Rota R Barenys M et al. Costeffectiveness of a ‘score and scope’ strategy for the management of dyspepsia. Eur J Gastroenterol Hepatol. Jul 2005;17(7):709-19. [Medline].

  • 38. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology. Feb 2000;118(2 Suppl 1):S2-8. [Medline].

  • 39. Graham DY Lew GM Lechago J. Antral G-cell and Dcell numbers in Helicobacter pylori infection: effect of H. pylori eradication. Gastroenterology. Jun 1993;104(6): 1655-60. [Medline].

  • 40. Nakajima S Krishnan B Ota H et al. Mast cell involvement in gastritis with or without Helicobacter pylori infection. Gastroenterology. Sep 1997;113(3):746-54. [Medline].

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 85 85 8
PDF Downloads 47 47 3